Roger A’Hern

31.4k total citations · 3 hit papers
282 papers, 20.5k citations indexed

About

Roger A’Hern is a scholar working on Oncology, Cancer Research and Surgery. According to data from OpenAlex, Roger A’Hern has authored 282 papers receiving a total of 20.5k indexed citations (citations by other indexed papers that have themselves been cited), including 146 papers in Oncology, 68 papers in Cancer Research and 55 papers in Surgery. Recurrent topics in Roger A’Hern's work include Breast Cancer Treatment Studies (52 papers), Estrogen and related hormone effects (36 papers) and HER2/EGFR in Cancer Research (31 papers). Roger A’Hern is often cited by papers focused on Breast Cancer Treatment Studies (52 papers), Estrogen and related hormone effects (36 papers) and HER2/EGFR in Cancer Research (31 papers). Roger A’Hern collaborates with scholars based in United Kingdom, United States and Canada. Roger A’Hern's co-authors include Mitch Dowsett, Janine Salter, Martin Gore, Janet Hardy, Ian E. Smith, Cyril Fisher, Patrick Stone, Kevin J. Harrington, Joseph Thomas and Jorge S. Reis‐Filho and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Roger A’Hern

278 papers receiving 19.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group

2011 1.5k citations Roger A’Hern, Janine Salter et al. profile →
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial

2011 1.2k citations Christopher M. Nutting, James P. Morden et al. The Lancet Oncology profile →
Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval

2010 745 citations Peter C.C. Fong, Timothy A. Yap et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Roger A’Hern United Kingdom	75	9.4k	5.4k	5.2k	4.0k	3.7k	282	20.5k
Geertruida H. de Bock Netherlands	65	5.9k 0.6×	3.0k 0.6×	4.3k 0.8×	3.4k 0.8×	2.2k 0.6×	650	18.7k
Hyman B. Muss United States	84	17.2k 1.8×	9.4k 1.7×	5.7k 1.1×	3.1k 0.8×	2.9k 0.8×	556	29.7k
Nadia Howlader United States	28	8.5k 0.9×	3.2k 0.6×	4.5k 0.9×	2.1k 0.5×	3.1k 0.8×	52	17.4k
William F. Anderson United States	55	8.9k 0.9×	4.6k 0.8×	3.9k 0.8×	4.6k 1.2×	3.6k 1.0×	134	21.6k
Sharon H. Giordano United States	76	10.8k 1.1×	7.4k 1.4×	4.1k 0.8×	2.9k 0.7×	2.2k 0.6×	408	20.8k
Stephen B. Edge United States	65	13.5k 1.4×	10.9k 2.0×	6.7k 1.3×	8.5k 2.1×	4.0k 1.1×	263	28.5k
Carsten Bokemeyer Germany	89	14.2k 1.5×	3.0k 0.6×	9.8k 1.9×	11.6k 2.9×	9.5k 2.6×	957	36.1k
Harry Bartelink Netherlands	74	7.1k 0.8×	9.1k 1.7×	5.4k 1.0×	5.2k 1.3×	2.4k 0.7×	270	20.5k
Susan Groshen United States	94	12.0k 1.3×	5.1k 0.9×	6.2k 1.2×	11.7k 2.9×	9.1k 2.5×	479	31.8k
Valter Torri Italy	66	8.8k 0.9×	2.5k 0.5×	7.2k 1.4×	3.8k 0.9×	2.6k 0.7×	305	21.2k

Countries citing papers authored by Roger A’Hern

Since Specialization

Citations

This map shows the geographic impact of Roger A’Hern's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roger A’Hern with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roger A’Hern more than expected).

Fields of papers citing papers by Roger A’Hern

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roger A’Hern. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roger A’Hern. The network helps show where Roger A’Hern may publish in the future.

Co-authorship network of co-authors of Roger A’Hern

This figure shows the co-authorship network connecting the top 25 collaborators of Roger A’Hern. A scholar is included among the top collaborators of Roger A’Hern based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roger A’Hern. Roger A’Hern is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

McGregor, Alison H., et al.. (2024). ‘I presumed the pain would eventually get better by itself’; challenges with access to rehabilitation for upper limb dysfunction after breast cancer treatment - Descriptive and qualitative findings from a cross-sectional survey. European Journal of Surgical Oncology. 50(10). 108591–108591. 3 indexed citations

Patani, Neill, Anita K. Dunbier, H Anderson, et al.. (2014). Differences in the Transcriptional Response to Fulvestrant and Estrogen Deprivation in ER-Positive Breast Cancer. Clinical Cancer Research. 20(15). 3962–3973. 16 indexed citations

Irshad, Sheeba, Cheryl Gillett, S Pinder, et al.. (2014). Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer. Breast Cancer Research and Treatment. 144(2). 331–341. 4 indexed citations

Ng, Charlotte K.Y., Britta Weigelt, Roger A’Hern, et al.. (2014). Predictive Performance of Microarray Gene Signatures: Impact of Tumor Heterogeneity and Multiple Mechanisms of Drug Resistance. Cancer Research. 74(11). 2946–2961. 15 indexed citations

Dunbier, Anita K., Zara Ghazoui, H Anderson, et al.. (2013). Molecular Profiling of Aromatase Inhibitor–Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance. Clinical Cancer Research. 19(10). 2775–2786. 98 indexed citations

Nutting, Christopher M., James P. Morden, Kevin J. Harrington, et al.. (2011). Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. The Lancet Oncology. 12(2). 127–136. 1202 indexed citations breakdown →

Haynes, Ben P., Anne Hege Straume, Jürgen Geisler, et al.. (2010). Intratumoral Estrogen Disposition in Breast Cancer. Clinical Cancer Research. 16(6). 1790–1801. 75 indexed citations

Fong, Peter C.C., Timothy A. Yap, David S. Boss, et al.. (2010). Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval. Journal of Clinical Oncology. 28(15). 2512–2519. 745 indexed citations breakdown →

Banerjee, Susana, Roger A’Hern, Simone Detre, et al.. (2010). Biological Evidence for Dual Antiangiogenic-Antiaromatase Activity of the VEGFR Inhibitor PTK787/ZK222584 In vivo. Clinical Cancer Research. 16(16). 4178–4187. 14 indexed citations

10.

Arnedos, Mónica, Ashutosh Nerurkar, Peter Osin, et al.. (2009). Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). Annals of Oncology. 20(12). 1948–1952. 142 indexed citations

11.

Dowsett, Mitch, Roger A’Hern, Janine Salter, Lila Zabaglo, & Ian E. Smith. (2009). Who would have thought a single Ki67 measurement would predict long-term outcome?. Breast Cancer Research. 11(S3). S15–S15. 17 indexed citations

12.

Marsden, Jo, et al.. (2003). More Breast Cancer Findings from the Women's Health Initiative. The Journal of the British Menopause Society. 9(3). 97–99. 1 indexed citations

13.

Marsden, Jo & Roger A’Hern. (2003). The Million Women Study and Breast Cancer. The Journal of the British Menopause Society. 9(3). 95–97. 5 indexed citations

14.

Ramanathan, Ramesh, et al.. (2001). Prognostic Index for Extremity Soft Tissue Sarcomas With Isolated Local Recurrence. Annals of Surgical Oncology. 8(4). 278–289. 46 indexed citations

15.

Marsden, Jo, Michael Baum, Roger A’Hern, et al.. (2001). The impact of hormone replacement therapy on breast cancer patients' quality of life and sexuality: a pilot study. The Journal of the British Menopause Society. 7(2). 85–91. 6 indexed citations

16.

Badve, Sunil, Roger A’Hern, Rosemary R. Millis, et al.. (1998). Prediction of local recurrence of ductal carcinoma in situ of the breast using five histological classifications: A comparative study with long follow-up. Human Pathology. 29(9). 915–923. 63 indexed citations

17.

Hardy, Janet, et al.. (1994). Prediction of survival in a hospital-based continuing care unit. European Journal of Cancer. 30(3). 284–288. 57 indexed citations

18.

HENDRY, W. F., Roger A’Hern, & Peter Cole. (1993). Was Young's syndrome caused by exposure to mercury in childhood?. BMJ. 307(6919). 1579–1582. 37 indexed citations

19.

Haybittle, J. L., Diana Brinkley, J. Houghton, Roger A’Hern, & Michael Baum. (1989). Postoperative radiotherapy and late mortality: evidence from the Cancer Research Campaign trial for early breast cancer.. BMJ. 298(6688). 1611–1614. 152 indexed citations

20.

Baum, Mark L. & Roger A’Hern. (1984). Adjuvant treatment with polyadenylic-polyuridylic acid in operable breast cancer. BMJ. 288(6422). 1009.1–1009. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact